Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients

Trabectedin and ifosfamide are among the few cytostatic agents active in advanced soft tissue sarcomas (STSs). Trabectedin is most potent against so-called L-sarcomas (leiomyosarcoma and liposarcoma). The survival gain and cost-effectiveness of these agents in a second-line setting were analysed in...

Descripción completa

Detalles Bibliográficos
Autores principales: Verboom, Michiel C., Gelderblom, Hans, Kerst, J. Martijn, Steeghs, Neeltje, Reyners, Anna K. L., Sleijfer, Stefan, van der Graaf, Winette T. A., van den Hout, Wilbert B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6589299/
https://www.ncbi.nlm.nih.gov/pubmed/31281207
http://dx.doi.org/10.1155/2019/3234205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6589299/
https://www.ncbi.nlm.nih.gov/pubmed/31281207
http://dx.doi.org/10.1155/2019/3234205

Ejemplares similares